Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue

Journal of Clinical Oncology

Volumn 26, Issue 30, 2008, Pages 4966-4972

  Hartmann, Elena ^a   Fernàndez, Verònica ^a   Moreno, Victor ^a   Valls, Joan ^a   Hernández, Luis ^a   Bosch, Francesc ^a   Abrisqueta, Pau ^a   Klapper, Wolfram ^a   Dreyling, Martin ^a   Hoster, Eva ^a   Müller Hermelink, Hans Konrad ^a   Ott, German ^a   Rosenwald, Andreas ^a   Campo, Elías ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; KI 67 ANTIGEN; PARAFFIN; RAN PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; TUMOR MARKER;

ACCURACY; ADULT; AGED; ALGORITHM; ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; FREEZING; GENETIC MODEL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; ONCOGENE; ONCOGENE MYC; OUTCOME ASSESSMENT; POLE2 GENE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; QUANTITATIVE GENETICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SLC29A2 GENE; TISSUE FIXATION; VALIDATION PROCESS; CRYOPRESERVATION; EVALUATION; GENE EXPRESSION; GENETICS; MIDDLE AGED; MORTALITY; PATHOLOGY; VALIDATION STUDY;

AGED; CRYOPRESERVATION; FEMALE; GENE EXPRESSION; HUMANS; KI-67 ANTIGEN; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; PARAFFIN EMBEDDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 54449085259     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.0410     Document Type: Article

References (59)

1. Fernàndez V, Hartmann E, Ott G, et al: Pathogenesis of mantle-cell lymphoma: All oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol 23:6364-6369, 2005
2. Campo E, Raffeld M, Jaffe ES: Mantle-cell lymphoma. Semin Hematol 36:115-127, 1999
3. Bertoni F, Rinaldi A, Zucca E, et al: Update on the molecular biology of mantle cell lymphoma. Hematol Oncol 24:22-27, 2006
4. Swerdlow SH, Williams ME: From centrocytic to mantle cell lymphoma: A clinicopathologic and molecular review of 3 decades. Hum Pathol 33:7-20, 2002
5. Bernard M, Gressin R, Lefrere F, et al: Blastic variant of mantle cell lymphoma: A rare but highly aggressive subtype. Leukemia 15:1785-1791, 2001
6. Bosch F, Lopez-Guillermo A, Campo E, et al: Mantle cell lymphoma: Presenting features, response to therapy, and prognostic factors. Cancer 82:567-575, 1998
7. Greiner TC, Moynihan MJ, Chan WC, et al: p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 87:4302-4310, 1996
8. Hernández L, Fest T, Cazorla M, et al: p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 87:3351-3359, 1996
9. Louie DC, Offit K, Jaslow R, et al: p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32). Blood 86: 2892-2899, 1995
10. Salaverria I, Zettl A, Bea S, et al: Specific Secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. J Clin Oncol 25:1216-1222, 2007
11. Rubio-Moscardo F, Climent J, Siebert R, et al: Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood 105:4445-4454, 2005
12. Pinyol M, Bea S, Pla L, et al: Inactivation of RB1 in mantle cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis. Blood 109:5422-5429, 2007
13. Rosenwald A, Wright G, Wiestner A, et al: The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 3:185-197, 2003
14. Tiemann M, Schrader C, Klapper W, et al: Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): A clinicopathological study from the European MCL Network. Br J Haematol 131:29-38, 2005
15. Katzenberger T, Petzoldt C, Holler S, et al: The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood 107:3407, 2006
16. Räty R, Franssila K, Joensuu H, et al: Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma. Eur J Haematol 69:11-20, 2002
17. de Jong D, Rosenwald A, Chhanabhai M, et al: Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: Validation of tissue microarray as a prerequisite for broad clinical applications - A study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 25:805-812, 2007
18. Jaffe ES, Harris NL, Stein H, et al (eds): World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France, IARC Press, 2001
19. Specht K, Richter T, Muller U, et al: Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol 158:419-429, 2001
20. Hernández L, Bea S, Pinyol M, et al: CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a/ARF locus. Cancer Res 65: 2199-2206, 2005
21. Pinyol M, Cobo F, Bea S, et al: P16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood 91:2977-2984, 1998
22. Beà S, Ribas M, Hernandez JM, et al: Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood 93:4365-4374, 1999
23. Beà S, Tort F, Pinyol M, et al: BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res 61:2409-2412, 2001
24. Pinyol M, Hernández L, Cazorla M, et al: Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. Blood 89:272-280, 1997
25. Cho-Vega JH, Rassidakis GZ, Admirand JH, et al: MCL-1 expression in B-cell non-Hodgkin's lymphomas. Hum Pathol 35:1095-1100, 2004
26. Fernàndez V, Jares P, Bea S, et al: Frequent polymorphic changes but not mutations of TRAIL receptors DR4 and DR5 in mantle cell lymphoma and other B-cell lymphoid neoplasms. Haematologica 89:1322-1331, 2004
27. Khoury JD, Medeiros LJ, Rassidakis GZ, et al: Expression of Mcl-1 in mantle cell lymphoma is associated with high-grade morphology, a high proliferative state, and p53 overexpression. J Pathol 199:90-97, 2003
28. MacFarlane M, Kohlhaas SL, Sutcliffe MJ, et al: TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res 65:11265-11270, 2005
29. Mestre-Escorihuela C, Rubio-Moscardo F, Richter JA, et al: Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood 109:271-280, 2007
30. Rubio-Moscardo F, Blesa D, Mestre C, et al: Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes. Blood 106:3214-3222, 2005
31. Tagawa H, Karnan S, Suzuki R, et al: Genome-wide array-based CGH for mantle cell lymphoma: Identification of homozygous deletions of the proapoptotic gene BIM. Oncogene 24:1348-1358, 2005
32. Marcé S, Molina-Arcas M, Villamor N, et al: Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. Haematologica 91:895-902, 2006
33. Bennaceur-Griscelli A, Bosq J, Koscielny S, et al: High level of glutathione-S-transferase pi expression in mantle cell lymphomas. Clin Cancer Res 10:3029-3034, 2004
34. Thieblemont C, Nasser V, Felman P, et al: Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. Blood 103:2727-2737, 2004
35. Pinyol M, Hernández L, Martinez A, et al: INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene. Am J Pathol 156:1987-1996, 2000
36. Hernández L, Hernandez S, Bea S, et al: C-myc mRNA expression and genomic alterations in mantle cell lymphomas and other nodal non-Hodgkin's lymphomas. Leukemia 13:2087-2093, 1999
37. Korz C, Pscherer A, Benner A, et al: Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes. Blood 99:4554-4561, 2002
38. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402-408, 2001
39. Witzig TE: Current treatment approaches for mantle-cell lymphoma. J Clin Oncol 23:6409-6414, 2005
40. Møller MB, Nielsen O, Pedersen NT: Oncoprotein MDM2 overexpression is associated with poor prognosis in distinct non-Hodgkin's lymphoma entities. Mod Pathol 12:1010-1016, 1999
41. Hartmann E, Fernandez V, Stoecklein H, et al: Increased MDM2 expression is associated with inferior survival in mantle cell lymphoma, but not related to the MDM2 SNP309. Haematologica 92:574-575, 2007
42. Wiestner A, Tehrani M, Chiorazzi M, et al: Point mutations and genomic deletions in Cyclin D1 create stable truncated mRNAs that are associated with increased proliferation rate and shorter survival in mantle cell lymphoma. Blood 109:4599-4606, 2007
43. Nagy B, Lundan T, Larramendy ML, et al: Abnormal expression of apoptosis-related genes in haematological malignancies: Overexpression of MYC is poor prognostic sign in mantle cell lymphoma. Br J Haematol 120:434-441, 2003
44. Arnaoutov A, Dasso M: The Ran GTPase regulates kinetochore function. Dev Cell 5:99-111, 2003
45. Dasso M: The Ran GTPase: Theme and variations. Curr Biol 12:R502-R508, 2002
46. Liu J, Levens D: Making myc. Curr Top Microbiol Immunol 302:1-32, 2006
47. Janz S: Myc translocations in B cell and plasma cell neoplasms. DNA Repair (Amst) 5:1213-1224, 2006
48. Lee SH, Shin MS, Kim HS, et al: Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma. Oncogene 20:399-403, 2001
49. Burgers PM: Eukaryotic DNA polymerases in DNA replication and DNA repair. Chromosoma 107:218-227, 1998
50. Hübscher U, Nasheuer HP, Syvaoja JE: Eukaryotic DNA polymerases, a growing family. Trends Biochem Sci 25:143-147, 2000
51. Baldwin SA, Beal PR, Yao SY, et al: The equilibrative nucleoside transporter family, SLC29. Pflugers Arch 447:735-743, 2004
52. Molina-Arcas M, Marce S, Villamor N, et al: Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells. Leukemia 19:64-68, 2005
53. Mizuno T, Nagamura H, Iwamoto KS, et al: RNA from decades-old archival tissue blocks for retrospective studies. Diagn Mol Pathol 7:202-208, 1998
54. Masuda N, Ohnishi T, Kawamoto S, et al: Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples. Nucleic Acids Res 27:4436-4443, 1999
55. Mies C: A simple, rapid method for isolating RNA from paraffin-embedded tissues for reverse transcription-polymerase chain reaction (RT-PCR). J Histochem Cytochem 42:811-813, 1994
56. Rupp GM, Locker J: Purification and analysis of RNA from paraffin-embedded tissues. Biotechniques 6:56-60, 1988
57. Stanta G, Bonin S: RNA quantitative analysis from fixed and paraffin-embedded tissues: Membrane hybridization and capillary electrophoresis. Biotechniques 24:271-276, 1998
58. Cronin M, Pho M, Dutta D, et al: Measurement of gene expression in archival paraffin-embedded tissues: Development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 164:35-42, 2004
59. Chen J, Byrne GE Jr, Lossos IS: Optimization of RNA extraction from formalin-fixed, paraffin-embedded lymphoid tissues. Diagn Mol Pathol 16:61-72, 2007